{"Symbol": "MNOV", "AssetType": "Common Stock", "Name": "MediciNova, Inc", "Description": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "4275 Executive Square, La Jolla, CA, United States, 92037", "FullTimeEmployees": "8", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "235620096", "EBITDA": "-16656604", "PERatio": "None", "PEGRatio": "-0.94", "BookValue": "1.606", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.368", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.1005", "ReturnOnEquityTTM": "-0.1598", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.263", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "18", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "3.5889", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "1.7456", "52WeekHigh": "9.19", "52WeekLow": "2.79", "50DayMovingAverage": "6.0117", "200DayMovingAverage": "5.2401", "SharesOutstanding": "44372900", "SharesFloat": "41672406", "SharesShort": "2309837", "SharesShortPriorMonth": "2161956", "ShortRatio": "0.57", "ShortPercentOutstanding": "0.05", "ShortPercentFloat": "0.0559", "PercentInsiders": "13.301", "PercentInstitutions": "21.816", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:10", "LastSplitDate": "2006-10-31"}